Effect of the chemokine receptor CCR5 in the development of American cutaneous leishmaniasis in a Southern Brazilian population

被引:5
作者
Ribas, Adriana Danmvolf [1 ]
Ribas, Rejane Cristina [1 ]
Da Silva Junior, Waldir Verissimo [2 ]
Alessi Aristides, Sandra Mara [3 ]
Campana Lonardoni, Maria Valdrinez [3 ]
Ehara Watanabe, Maria Angelica [4 ]
Borelli, Sueli Donizete [5 ]
Verzignassi Silveira, Thais Gomes [3 ]
机构
[1] Univ Estadual Maringa, Dept Clin Analyses & Biomed, Postgrad Program Hlth Sci, BR-87020900 Maringa, Parana, Brazil
[2] Univ Estadual Maringa, Dept Clin Analyses & Biomed, Dept Biostat, BR-87020900 Maringa, Parana, Brazil
[3] Univ Estadual Maringa, Dept Clin Analyses & Biomed, Lab Leishmaniasis, BR-87020900 Maringa, Parana, Brazil
[4] Univ Estadual Londrina, Dept Pathol Sci, BR-86051990 Londrina, Parana, Brazil
[5] Univ Estadual Maringa, Dept Basic Hlth Sci, Immunogenet Lab, BR-87020900 Maringa, Parana, Brazil
关键词
American cutaneous leishmaniasis; CCR5; chemokines; DELTA-32; POLYMORPHISM; GENE; INDIVIDUALS; ASSOCIATION; RESISTANCE; FREQUENCY; ALLELE;
D O I
10.3892/mmr.2013.1452
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
American cutaneous leishmaniasis (ACL) shows a wide spectrum of clinical and immunopathological manifestations. The CCR5 chemokine receptor directs the immune response to a Thl pattern and the mutant allele of this genotype (Delta 32/Delta 32) results in a less effective response, thus leading to a milder inflammation. The objective of the present study was to investigate the effect of the CCR5 chemokine receptor in the pathogenesis of ACL in a population of Southern Brazil. The frequency of the genotypes and their association with ACL were studied in 111 patients and compared with 218 control subjects. Genotyping was performed using samples amplified by polymerase chain reaction with sequence specific primers (PCR-SSP). The groups varied in chronological age (P<0.00001), but showed no differences in gender (P=0.0696) or ethnicity (P=0.2944). The frequency of the CCR5/Delta 32 genotype did not differ between the patient and control groups (P=0.3009). The Delta 32/Delta 32 deletion was not observed in any individual involved in the study. The analysis of the genotypes observed no significant difference in the frequency of the CCR5/Delta 32 genotype between the ACL and control groups, however the subgroup of patients with a recurrence of the lesion showed a higher frequency of the CCR5/Delta 32 mutation (P=0.020), indicating a possible effect of this allele-in the pathogenesis of ACL. Nevertheless, more studies are required to elucidate the role of CCR5 in the pathogenesis of ACL.
引用
收藏
页码:189 / 194
页数:6
相关论文
共 50 条
[21]   Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor [J].
Saita, Yuji ;
Kondo, Mitsuhiro ;
Shimizu, Yasuaki .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2007, 7 (12) :1528-1534
[22]   Lack of Association Between Chemokine Receptor 5 (CCR5) δ32 Mutation and Pathogenesis of Asthma in Iranian Patients [J].
Abousaidi, Hamid ;
Vazirinejad, Reza ;
Arababadi, Mohammad Kazemi ;
Rafatpanah, Houshang ;
Pourfathollah, Ali Akbar ;
Derakhshan, Reza ;
Daneshmandi, Saeed ;
Hassanshahi, Gholamhossein .
SOUTHERN MEDICAL JOURNAL, 2011, 104 (06) :422-425
[23]   The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis [J].
Moller, M. ;
Sondergaard, H. B. ;
Koch-Henriksen, N. ;
Sorensen, P. S. ;
Sellebjerg, F. ;
Oturai, A. B. .
ACTA NEUROLOGICA SCANDINAVICA, 2014, 129 (01) :27-31
[24]   Relationship of Genetic Polymorphisms of the Chemokine, CCL5, and Its Receptor, CCR5, with Coronary Artery Disease in Taiwan [J].
Ting, Ke-Hsin ;
Ueng, Kwo-Chang ;
Chiang, Whei-Ling ;
Chou, Ying-Erh ;
Yang, Shun-Fa ;
Wang, Po-Hui .
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2015, 2015
[25]   The chemoattraction of lymphocytes by rheumatoid arthritis - synovial fluid is not dependent on the chemokine receptor CCR5 [J].
Santiago, B ;
Galindo, M ;
Rivero, M ;
Brehmer, MT ;
Mateo, I ;
Pablos, JL .
RHEUMATOLOGY INTERNATIONAL, 2002, 22 (03) :107-111
[26]   Relationship Between the Chemokine Receptor CCR5 and Microglia in Neurological Disorders: Consequences of Targeting CCR5 on Neuroinflammation, Neuronal Death and Regeneration in a Model of Epilepsy [J].
Louboutin, Jean-Pierre ;
Strayer, David S. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2013, 12 (06) :815-829
[27]   Impact of Chemokine Receptor CCR2 and CCR5 Gene Polymorphism on Allograft Outcome in North Indian Renal Transplant Recipients [J].
Singh, R. ;
Kapoor, R. ;
Srivastava, A. ;
Mittal, R. D. .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2009, 69 (01) :51-56
[28]   Cysteine-cysteine chemokine receptor 5 (CCR5) profile of HIV-infected subjects attending University of Calabar Teaching Hospital, Calabar, Southern Nigeria [J].
Ekere, Ekerette Friday ;
Useh, Monday F. ;
Okoroiwu, Henshaw Uchechi ;
Mirabeau, Tatfeng Youtchou .
BMC INFECTIOUS DISEASES, 2020, 20 (01)
[29]   CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis [J].
I Zapico ;
E Coto ;
A Rodríguez ;
C Alvarez ;
JC Torre ;
V Alvarez .
Genes & Immunity, 2000, 1 :288-289
[30]   Mutations in C-C chemokine receptor type 5 (CCR5) in South African individuals [J].
Barmania, Fatima ;
Potgieter, Marnie ;
Pepper, Michael S. .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2013, 17 (12) :E1148-E1153